CRDL übertreffen die 15 der letzten 21Schätzungen.
71%
Nächster Bericht
Datum des nächsten Berichts
30. März 2026
Estimate forQ4 25(Revenue/ EPS)
--
/
-$0.08
Implizierte Änderung vonQ3 25(Revenue/ EPS)
--
/
-33.33%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
--
/
-11.11%
Cardiol Therapeutics Inc. Class A Common Shares earnings per share and revenue
On 13. Nov. 2025, CRDL reported earnings of -0.12 USD per share (EPS) for Q3 25, missing the estimate of -0.09 USD, resulting in a -30.72% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.08 USD, with revenue projected to reach -- USD, implying an decrease of -33.33% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Citius Pharmaceuticals Inc. Common
Report Date
26. Dez. 2025 For Q4 25
Estimate
-$0.49
Aktuell
-
Überraschung
-
FAQ
What were Cardiol Therapeutics Inc. Class A Common Shares's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Cardiol Therapeutics Inc. Class A Common Shares reported EPS of -$0.12, missing estimates by -30.72%, and revenue of $0.00, 0% as expectations.
How did the market react to Cardiol Therapeutics Inc. Class A Common Shares's Q3 2025 earnings?
The stock price moved -- 0%, changed from $1.02 before the earnings release to $1.02 the day after.
When is Cardiol Therapeutics Inc. Class A Common Shares expected to report next?
The next earning report is scheduled for 30. März 2026.
What are the forecasts for Cardiol Therapeutics Inc. Class A Common Shares's next earnings report?
Based on 3
analysts, Cardiol Therapeutics Inc. Class A Common Shares is expected to report EPS of -$0.08 and revenue of -- for Q4 2025.